(Q36474106)

14 August 2017

Salvage therapy for hepatocellular carcinoma with thalidomide (English)

1 reference

14 August 2017

0 references

hepatocellular carcinoma

1 reference

7

Ruey-Kuen Hsieh

1 reference

14 August 2017

Tsang-En Wang

1

1 reference

14 August 2017

Chin-Roa Kao

2

1 reference

14 August 2017

Shee-Chan Lin

3

1 reference

14 August 2017

Wen-Hsiung Chang

4

1 reference

14 August 2017

Cheng-Hsin Chu

5

1 reference

14 August 2017

Johson Lin

6

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

World Journal of Gastroenterology

14 August 2017

1 reference

14 August 2017

10

1 reference

14 August 2017

5

1 reference

14 August 2017

649-653

1 reference

Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide: from tragedy to promise

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide: current and potential clinical applications

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Heterogeneity of DNA content in multiple synchronous hepatocellular carcinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide is an inhibitor of angiogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Induction of angiogenesis during the transition from hyperplasia to neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

In vivo assessment of angioarchitecture and microcirculation in experimental liver cancer: a new model in rats

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4716902

Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males

21 September 2018

1 reference

12 December 2020

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

12 December 2020

Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features

1 reference

12 December 2020

Preparing for thalidomide's comeback

1 reference

12 December 2020

Antitumor effect of the angiogenesis inhibitor TNP-470 on human digestive organ malignancy

1 reference

12 December 2020

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

1 reference

12 December 2020

Tumor necrosis factor-alpha production by human hepatoma cell lines is resistant to drugs that are inhibitory to macrophages

1 reference

12 December 2020

Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V10.I5.649

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

14991931

1 reference